Squamous-cell carcinomas of the lung: Emerging biology, controversies, and the promise of targeted therapy Journal Article
| Authors: | Drilon, A.; Rekhtman, N.; Ladanyi, M.; Paik, P. |
| Article Title: | Squamous-cell carcinomas of the lung: Emerging biology, controversies, and the promise of targeted therapy |
| Abstract: | Squamous-cell carcinomas of the lung (SQCLCs) are defined by unique clinicopathological and molecular characteristics that have evolved substantially over time. Historically, these neoplasms were the most common subtype of non-small-cell lung cancers and were regarded as central tumours with high molecular complexity without targetable genetic abnormalities. Today, the incidence of SQCLCs is surpassed by adenocarcinomas of the lung with a shift towards peripheral squamous tumours. Differential responses to cytotoxic and biological treatments have reshaped our approach to standard therapies. Additionally, evidence of unique biology has emerged with the discovery of SOX2 amplification, NFE2L2 and KEAP1 mutations, PI3K pathway changes, FGFR1 amplification, and DDR2 mutations. These discoveries have ushered in a new era of targeted therapeutic agents for patients with this disease. This Review draws attention to the distinct clinical and pathological characteristics of SQCLCs, summarises present experience with existing cytotoxic and targeted therapies, and discusses emerging treatments based on new insights into the biology of this disease. © 2012 Elsevier Ltd. |
| Keywords: | signal transduction; protein expression; treatment response; gene mutation; single nucleotide polymorphism; proto-oncogene proteins; histopathology; review; carcinoma, squamous cell; bevacizumab; cisplatin; erlotinib; drug efficacy; drug safety; nonhuman; gemcitabine; paclitaxel; cancer incidence; sensitivity and specificity; imatinib; gene overexpression; carboplatin; gene amplification; gene expression profiling; lung neoplasms; epidermal growth factor receptor; membrane proteins; genetic variability; dasatinib; cetuximab; phosphatidylinositol 3 kinase; morphology; carcinogenesis; cell transformation, neoplastic; oncogene; patient care; lung adenocarcinoma; fluorescence in situ hybridization; gene rearrangement; rna, messenger; intracellular signaling peptides and proteins; protein p63; cancer epidemiology; heterozygosity loss; receptor protein-tyrosine kinases; ras proteins; lung squamous cell carcinoma; platinum complex; taxane derivative; cytokeratin 5; cytokeratin 6; nilotinib; ubiquitin protein ligase e3; pemetrexed; transcription factor sox2; soxb1 transcription factors; lung hemorrhage; phosphatidylinositol 3-kinases; keratinization; transcription factor nrf2; 1 tert butyl 3 [6 (3,5 dimethoxyphenyl) 2 (4 diethylaminobutylamino)pyrido[2,3 d]pyrimidin 7 yl]urea; kelch like ech associated protein 1; ddr2 gene; fgfr1 gene; keap1 gene; nfe2l2 gene; sox2 gene; receptors, mitogen |
| Journal Title: | Lancet Oncology |
| Volume: | 13 |
| Issue: | 10 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2012-10-01 |
| Start Page: | e418 |
| End Page: | e426 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(12)70291-7 |
| PROVIDER: | scopus |
| PUBMED: | 23026827 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 November 2012" - "CODEN: LOANB" - "Source: Scopus" |
Altmetric
Citation Impact
Related MSK Work